remove_red_eye 502 Views
#Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Pulmonary Medicine
The US Food and Drug Administration (FDA) has approved delafloxacin (Baxdela, Melinta Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria, according to a company news release.
This is the second indication for the fluoroquinolone antibiotic. Approval of delafloxacin for CABP was based on positive results from a phase 3, randomized, double-blind trial comparing the efficacy and safety of delafloxacin to moxifloxacin… (Medscape)